As featured in ...
Please visit our Free Tools page to get a FREE copy of our step-by-step guides and tools to increase your effectiveness.
Project Execution and Implementation, PMO Design and Setup, Change Management, ERP Analysis and Selection and more...
Find out what sets CompassX apart. We execute business critical projects, navigating our client's strategies to success.
The Affordable Care Act has excessively publicized the concept of public health insurance exchanges. But most have heard little about Private Health Insurance Exchanges (PHIXs). Private Health Insurance Exchanges (PHIXs) are marketplaces where employees of private companies can purchase their own health insurance in a retail, “Amazon-like”, self-directed fashion. “Health insurance in the U.S. is at the cusp of a major transition from an employer driven payor model to a model directly involving...30 - June - 2014
China has undergone significant transformation in its beauty and personal care industry over the past decade. Beauty is now big business in China. The country’s cosmetic market is now the third-largest in the world, with $26 billion in sales last year. The market has grown at an annualized 11% rate since 2009. Foreign cosmetic firms have had to adapt their offerings and marketing strategies to maintain their leadership in an increasingly competitive cosmetic market. The key foreign...30 - June - 2014
Targeted drug therapies continue to offer glimpses of breakthrough drug discoveries. Although the ultimate goal is to treat and cure diseases, this same molecular targeting is proving to be superior in diagnosing various medical conditions. Take, for example, Exact Sciences, who recently received an unanimous vote of conﬁdence to have the FDA approve their DNA targeted diagnostic test. The test uses DNA markers to ﬂag the presence of colon cancer. In the one-and-one-half...31 - May - 2014
In fact, the acquisition market is at its hottest level since 1999. According to the International Strategy & Investment Group, 131 merger-and-acquisition and other deals, worth more than $1.2 trillion, 'bloomed' since the start of 2014. Amongst the largest announcements in the Health sector this month, Valeant Pharmaceutical's hostile bid for Allergan. Below, I explain why this proposed deal is far from certain and my early predictions. Why the Valeant deal is unlikely to...30 - April - 2014
Last month, I mentioned viewing what will be the first of many media spots for Gilead's new Hepatitis C blockbuster drug, Sovaldi. What can you learn from the development, approval and launch of this blockbuster? I predict these three trends will continue gaining momentum within the industry. Partnering through Acquisitions You won't be surprised to hear that the discovery of Sovaldi didn't come directly from Gilead's scientists. Sovaldi was acquired when Gilead purchased...31 - March - 2014
Last week, I watched the first, of what will be many, media spots for Gilead's new product, Sovaldi. Sovaldi will potentially become the largest product launch in drug history with expectations to generate $2-3 B in revenue, just in 2014 alone. Gilead's product provides an oral cure for chronic Hepatitis C, a virus that has infected over 3 million people in the United States and 150 million people worldwide. More people die each year in the United States from CHC than from HIV. I will...28 - February - 2014